Get notified when QTTB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Substantial Dilution (new) — The offering price is expected to be significantly above the $3.17 net tangible book value per share, causing steep dilution to new investors.
Q32 Bio files $200M mixed shelf offering of common stock and pre-funded warrants; terms not yet set
Filed July 13, 2026 · ~1 min read
Key Changes
-
high
Q32 Bio is offering common stock and pre-funded warrants with a total offering amount of $200 million, but the number of shares and per-share price are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
medium
The company's stock last traded at $11.21 per share on July 10, 2026, providing a reference point for the eventual offering price.
The Offering verify on EDGAR → -
high
Net proceeds will be used for working capital, including advancing lead candidate bempikibart into future clinical trials.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade QTTB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify